Vera Therapeutics, Inc. (VERA) Stock Forecast
VERA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 15 analysts
- Price target
- $74.20 average of analyst targets
- Upside to target
- +166.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-1.71
- 52-week range
- $24.10 – $55.67
VERA analyst ratings
15 analystsNumber of analysts at each rating.
VERA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VERA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.61 | −$1.80 | −$1.39 | −$1.26 | −27.6% | 9 |
| Current fiscal year (2026) | −$6.25 | −$7.23 | −$5.77 | −$4.66 | −34.2% | 10 |
| Next fiscal year (2027) | −$4.25 | −$6.72 | −$2.23 | −$6.25 | +32.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VERA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.7M | $0 | $8.7M | 0.0% | 13 |
| Current fiscal year (2026) | $24.1M | $12.7M | $51.0M | 0.0% | 12 |
| Next fiscal year (2027) | $232.4M | $133.7M | $346.9M | +863.1% | 12 |
VERA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VERA revenue: reported and forecast
VERA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.54 | −$1.64 | −$1.62 | −$1.62 | −$1.61 | +4.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$6.21 | −$6.37 | −$6.27 | −$6.24 | −$6.25 | +0.7% | 1 up · 1 down |
| Next fiscal year (2027) | −$3.86 | −$4.36 | −$4.37 | −$4.26 | −$4.25 | +10.2% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VERA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VERA beat in 3 of 12.
What analysts expect from VERA
15 analysts cover Vera Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $74.20, 166.1% above the latest close of $27.88. Analysts expect earnings of −$6.25 per share for 2026, −34.2% from a year earlier. For 2027 the average estimate is −$4.25 per share on revenue of $232.4 million. Vera Therapeutics beat the EPS estimate in 3 of the last 12 quarters.
Related: VERA income statement, VERA key metrics, VERA chart. See the VERA stock overview for the latest quote and news.
VERA forecast FAQ
What is Vera Therapeutics's price target?
The average analyst price target for Vera Therapeutics is $74.20, 166.1% above the latest close of $27.88.
Is Vera Therapeutics a buy, hold or sell?
Of 15 analysts covering Vera Therapeutics, 12 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vera Therapeutics's EPS forecast?
Analysts forecast −$6.25 per share for 2026 (range −$7.23 to −$5.77); for 2027 the estimate is −$4.25.
What is Vera Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $24.1 million, growth of 0.0%; for 2027 it is $232.4 million.
When does Vera Therapeutics report earnings?
Vera Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-1.71.
Does Vera Therapeutics usually beat earnings estimates?
Vera Therapeutics reported EPS at or above the analyst estimate in 3 of the last 12 quarters.